110 related articles for article (PubMed ID: 28855993)
1. Treatment sequence in castration-resistant prostate cancer: A retrospective study in the new anti-androgen era.
Hoshi S; Numahata K; Ono K; Yasuno N; Bilim V; Hoshi K; Amemiya H; Sasagawa I; Ohta S
Mol Clin Oncol; 2017 Oct; 7(4):601-603. PubMed ID: 28855993
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel.
Li JR; Chiu KY; Wang SS; Yang CK; Chen CS; Ho HC; Hung CF; Cheng CL; Yang CR; Chen CC; Wang SC; Lin CY; Chang CH; Hsu CY; Ou YC
Front Pharmacol; 2017; 8():836. PubMed ID: 29213237
[No Abstract] [Full Text] [Related]
4. [CLINICAL OUTCOMES OF ABIRATERONE ACETATE FOR TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER: A RETROSPECTIVE ANALYSIS].
Hasumi M; Kato M; Otsu A; Muramatsu K; Shimizu N
Nihon Hinyokika Gakkai Zasshi; 2019; 110(3):177-184. PubMed ID: 32684578
[TBL] [Abstract][Full Text] [Related]
5. [Treatment sequence using newly developed agents for men with castration resistant prostate cancer].
Fujimoto N
Nihon Rinsho; 2014 Dec; 72(12):2193-7. PubMed ID: 25518357
[TBL] [Abstract][Full Text] [Related]
6. No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer.
Tanaka M; Kimura T; Iwamura Y; Enei Y; Iwamoto Y; Imai Y; Inaba Y; Matsukawa A; Onuma H; Ito K; Mori K; Sasaki H; Miki J; Furuta A; Miki K; Egawa S
Prostate; 2019 Oct; 79(14):1604-1610. PubMed ID: 31376184
[TBL] [Abstract][Full Text] [Related]
7. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
[TBL] [Abstract][Full Text] [Related]
8. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
Azad AA; Leibowitz-Amit R; Eigl BJ; Lester R; Wells JC; Murray RN; Kollmannsberger C; Heng DY; Joshua AM; Chi KN
Prostate; 2014 Nov; 74(15):1544-50. PubMed ID: 25175831
[TBL] [Abstract][Full Text] [Related]
9. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
Bellmunt J; Kheoh T; Yu MK; Smith MR; Small EJ; Mulders PF; Fizazi K; Rathkopf DE; Saad F; Scher HI; Taplin ME; Davis ID; Schrijvers D; Protheroe A; Molina A; De Porre P; Griffin TW; de Bono JS; Ryan CJ; Oudard S
Eur Urol; 2016 May; 69(5):924-32. PubMed ID: 26508309
[TBL] [Abstract][Full Text] [Related]
10. [CLINICAL STUDY OF SEQUENTIAL THERAPY WITH ABIRATERONE AND ENZALUTAMIDE FOLLOWING DOCETAXEL THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER].
Miyamae K; Kitani K; Hara K; Nakakuma K; Hamada S; Hamada Y
Nihon Hinyokika Gakkai Zasshi; 2017; 108(2):74-79. PubMed ID: 29669980
[TBL] [Abstract][Full Text] [Related]
11. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
12. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
13. Baseline prostate-specific antigen levels following treatment with abiraterone acetate as a prognostic factor in castration-resistant prostate cancer.
Hiroshige T; Eguchi Y; Yoshizumi O; Chikui K; Kumagai H; Kawaguchi Y; Onishi R; Hayashi T; Watanabe K; Mitani T; Saito K; Igawa T
Oncol Lett; 2018 May; 15(5):6806-6814. PubMed ID: 29725416
[TBL] [Abstract][Full Text] [Related]
14. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
[TBL] [Abstract][Full Text] [Related]
15. A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients.
James A; Vincent B; Sivadas A; Pavithran K
Int J Hematol Oncol Stem Cell Res; 2018 Jan; 12(1):4-7. PubMed ID: 29951171
[No Abstract] [Full Text] [Related]
16. [INITIAL EXPERIENCE OF THE ENZALUTAMIDE TREATMENT FOR CASTRATION-RESISTANT PROSTATE CANCER].
Igarashi A; Fukagai T; Morita M; Hayashi K; Koshikiya A; Ogawa Y; Fuji K; Naoe M; Morita J; Oshinomi K; Nakazato T; Ogawa Y; Matsui Y; Shimada M; Inoue K; Saito K; Ogawa Y; Matsumoto Y; Sasaki H; Ota M; Yamamoto K; Shimoyama H; Imamura Y; Yamagishi M; Tanifuji S; Ishihara M; Shichijyo T; Sato N; Omori K; Matsubara E
Nihon Hinyokika Gakkai Zasshi; 2016; 107(3):155-161. PubMed ID: 28740046
[TBL] [Abstract][Full Text] [Related]
17. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
18. Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer.
Tagawa ST; Posadas EM; Bruce J; Lim EA; Petrylak DP; Peng W; Kheoh T; Maul S; Smit JW; Gonzalez MD; De Porre P; Tran N; Nanus DM
Eur Urol; 2016 Nov; 70(5):718-721. PubMed ID: 26852075
[TBL] [Abstract][Full Text] [Related]
19. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study.
Cindolo L; Natoli C; De Nunzio C; De Tursi M; Valeriani M; Giacinti S; Micali S; Rizzo M; Bianchi G; Martorana E; Scarcia M; Ludovico GM; Bove P; Laudisi A; Selvaggio O; Carrieri G; Bada M; Castellan P; Boccasile S; Ditonno P; Chiodini P; Verze P; Mirone V; Schips L
BMC Cancer; 2017 Nov; 17(1):753. PubMed ID: 29126389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
